Using the drop-down menu below, read about highlighted scientific news for patients from ASCO's Annual Meetings, Symposia, and medical journals for the past three years. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
This includes ASCO’s Journal of Clinical Oncology and its scientific meetings, including the ASCO Annual Meeting, a five-day meeting held each May/June. To read the Annual Meeting summaries compiled into a yearly newsletter, you can also review Research Round Up: News for Patients from the ASCO Annual Meeting. Don’t forget to check out audio podcasts and videos about this news, as well. And a list of upcoming Symposia can be found here. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at different ASCO meetings. To search the entire collection of meeting abstracts, visit ASCO's website.
Results from a long-term study on stage I seminoma show that surveillance, or watching for a cancer recurrence (cancer that comes back after treatment), is a safe option for most men. Seminoma is a type of testicular cancer that is generally slow growing and makes up about half of all testicular cancer diagnoses. In stage I seminoma, the tumor has not spread to the lymph nodes (tiny, bean-shaped organs that fight infection) or other parts of the body. Surgery is usually the first treatment given. Surveillance includes physical examinations and imaging and blood tests for five years. In the United States, about half of patients are monitored for a recurrence and the other half receives either radiation therapy or chemotherapy to help prevent a recurrence.
Results from an early, ongoing study suggest that pairing the drug ipilimumab (Yervoy) with a new drug called nivolumab works better to shrink advanced melanoma. Currently, ipilimumab is a standard treatment option for advanced melanoma in many countries. Nivolumab, when used by itself, has been shown to effectively treat melanoma, as well as other cancers, in previous studies. Both nivolumab and ipilimumab are types of immunotherapy, a treatment designed to boost the body’s natural defenses to fight the cancer. It uses materials either made by the body or in a laboratory to improve, target, or restore immune system function. Specifically, nivolumab targets PD-1 and ipilimumab targets CTLA-4, which are both found on the surface of tumor cells and keep the immune system from destroying the cancer. These drugs stop PD-1 and CTLA-4 from working so the immune system can get rid of the cancer.
A new type of targeted immunotherapy (called MPDL3280A) was able to shrink several different types of cancer, including lung, melanoma, kidney, colorectal, and stomach cancers in patients whose cancer had worsened while receiving other treatments. Immunotherapy is designed to boost the body’s natural defenses to fight the cancer. It uses materials either made by the body or in a laboratory to improve, target, or restore immune system function. Specifically, this new treatment targets PD-L1, a protein on the surface of tumor cells that prevents the immune system from fighting the tumor. Basically, this treatment stops PD-L1 from working, which then allows the body’s immune system to fight the cancer.
In a large, 20-year study, researchers found that men with a high level of fitness at middle age have a lower risk of developing and dying from lung and colorectal cancers. They also found that better fitness lowers the risk of dying of prostate cancer.
Patients with stage III non-small cell lung cancer (NSCLC) who participated in a recent study lived longer and had fewer side effects when they received the standard dose of radiation therapy and not the high-dose radiation therapy. Stage III NSCLC is usually difficult or impossible to remove with surgery. Radiation therapy is used to slow the growth and spread of the cancer to lengthen patients’ lives. The standard dose for radiation therapy is 60 Gray (Gy), a measurement of how much radiation is absorbed by the body, although many doctors use higher doses in the hope of better controlling the cancer’s growth.
A recent study showed that the drug trametinib slowed tumor growth and lengthened the lives of patients who have advanced melanoma with a BRAF gene mutation (change). Trametinib is a type of treatment called targeted therapy. Targeted therapy targets the cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. Currently, there is one targeted therapy approved to treat melanoma that targets the BRAF gene, called vemurafenib (Zelboraf). However, vemurafenib eventually stops controlling melanoma growth for most patients, highlighting the need for other treatment options. Trametinib targets the MEK protein, which affects melanoma growth similarly to a mutated BRAF gene, which is why researchers are studying this treatment for melanoma.
A new study showed that the targeted drug regorafenib is an effective treatment for patients with gastrointestinal stromal tumor (GIST) that has worsened because the other available treatments have stopped working. Targeted therapy is a treatment that targets a tumor's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. Specifically, regorafenib targets an abnormal enzyme called KIT. The currently available GIST treatments, imatinib (Gleevec) and sunitinib (Sutent), often slow or stop tumor growth at first, but eventually the drugs stop working and the cancer continues to grow. Regorafenib appears to work in a different way, even helping to slow GIST growth when other treatments are no longer working.
In a recent international study, researchers found that the targeted therapy drug afatinib kept advanced non-small cell lung cancer (NSCLC) with mutations (changes) to the epidermal growth factor receptor (EGFR) from worsening longer than the standard treatment. Targeted therapy is a treatment that targets a cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. Specifically, afatinib targets EGFR. In a healthy cell, EGFR allows cells to grow and divide. When there are too many receptors caused by a mutation, as happens in cancer, the cancer cells continue to grow and divide uncontrollably.
Researchers found that the drug dabrafenib reduced the risk of melanoma worsening and the risk of death from the disease when compared with chemotherapy in a new, large study of melanoma. Dabrafenib is a targeted drug. This treatment targets the cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. Specifically, dabrafenib targets a mutation (change) in the BRAF gene, which is known to fuel melanoma growth. Another drug recently used for melanoma, vemurafenib (Zelboraf), also targets the BRAF mutation.
In a new study, researchers found that the drug duloxetine (Cymbalta) helps treat a painful side effect of chemotherapy called peripheral neuropathy. Peripheral neuropathy is a condition that occurs when nerves in the body's peripheral nervous system (outside the brain and spinal cord) are damaged. Depending on where the damaged nerves are located, it can cause numbness and tingling in the hands and feet, pain, muscle weakness, constipation, and dizziness.